Rapidly developing disruptive treatments for today’s most challenging diseases
Eikonoklastes is an early stage biopharmaceutical company focused on rapidly advancing innovative medicines for numerous areas of significant unmet medical need, starting with neurodegenerative diseases and cancers.
We’re relentlessly striving to rapidly advance a new generation of medicines where value is most efficiently generated. Most importantly, we will significantly improve the lives of patients and families suffering from the most devastating diseases.
We are iconoclasts passionate about building a new kind of biotech company. One that breaks the mold by developing a pipeline of novel compounds initially tailored toward areas with the strongest benefit/risk (e.g., rare disease and oncology) and then collaborating with strategic partners to further explore the immense potential in larger indications.
Eikonoklastes is pushing the frontiers in multiple areas of severe unmet clinical need. Our dynamic discovery and development approach allows us to focus on accelerated approvals and outsized returns for multiple compounds. Our first two assets are on track for Phase 1/2a studies in 2023, with several additional therapies and potential partnerships on the horizon.
SynCav1 is a first-in-class, non-monogenic gene therapy platform to treat a wide range of neurodegenerative diseases with precise, targeted overexpression of Caveolin-1.
Engineered for safety
Intraspinal delivery minimizes dose requirements and significantly reduces systemic exposure and thus the possibility of liver toxicity and immunogenicity.
Demonstrated improvement in quality of life and survival in Amyotrophic Lateral Sclerosis (ALS) models and improved memory in Alzheimer’s disease models.
LEAD INDICATION: Our lead indication is ALS, which is eligible for Orphan Drug and Breakthrough designation. ALS is a rare neurological disease with significant socioeconomic impact whose patients are desperate for novel safe and effective therapies.
Delivering additional copies of a specific gene to induce neuroprotection
SynCav1 is a gene therapy that has been engineered by Dr. Brian Head to overexpress Caveolin-1, which organizes and regulates synaptic receptors essential for neuromuscular signaling and function. Research has shown that increasing Caveolin-1 leads to a neuroprotective effect so that nerve cells can compensate for the neurodegenerative process caused by the underlying disease, allowing the cells to stay healthier and improving their functional ability. This increase leads to healthier nerve cells and better communication between them. By maintaining nerve cell health, SynCav1 could be an option for a wide range of neurodegenerative diseases.
L-ICON3 is a novel tissue factor (TF)-targeting immunoconjugate agent, with enhanced delivery and efficacy against multiple solid tumors and other pathologic conditions.
Proprietary, state of the art molecule discovered and engineered by scientific founder, Dr Zhiwei Hu—one of the early pioneers of TF-targeting therapies.
Optimized for efficacy
Designed for greater potency and selectivity, improved safety, and immune activation.
LEAD INDICATION: Our lead indication is Triple Negative Breast Cancer (TNBC), which accounts for 15% of all breast cancers. TNBC is an aggressive cancer and in most cases considered incurable with an 18-month life expectancy from initial diagnosis.
Launching a 3-pronged immune attack on the tumor microenvironment
L-ICON3 is a conjugate technology targeting tissue factor for the treatment of solid tumors and other pathologic conditions. The immune conjugate is engineered with a natural high affinity ligand for tissue factor, conjugated to an IgG3 Fc. This allows the compound to bind to the tumor cells, neovasculature supplying blood to the tumors, and the tumor stem cells, to trigger complement activation (CDC) and antibody dependent cellular cytotoxicity (ADCC) killing of the pathologic cells.
|Traumatic Brain Injury|
- Director, New Drug Development, P&G Pharmaceuticals
- Co-founder, Myonexus Therapeutics
- COO, N8 Medical, Kinnear Pharmaceuticals and Myonexus Therapeutics
Dr. Bruce Halpryn co-founded Eikonoklastes in 2019 and has served as Chairman of our Board of Directors, President, and Chief Executive Officer since 2019. Dr. Halpryn has more than 30 years of experience in the industry with involvement in the formation and the leadership of four early stage biotechnology companies as well as global biopharmaceutical companies. Prior to Eikonoklastes, Bruce co-founded Myonexus Therapeutics (acquired by Sarepta in 2018), and served as Chief Operating Officer and as a member of its Board of Directors. Dr. Halpryn has extensive experience in designing and leading biologics and small molecule drug development programs and companies across a broad range of therapeutic areas.
Earlier in his career, Dr. Halpryn led the Congestive Heart Failure Research Lab at Norwich Eaton Pharmaceuticals before its acquisition by the Proctor & Gamble Company and subsequently renamed P&G Pharmaceuticals. He then led drug discovery, development, and commercialization efforts for P&G Pharmaceuticals, playing a key role in the strategic design and program leadership of numerous successful approvals.
Bruce is a cardiovascular physiologist by education and conducted his post-doctoral fellowship as a National Research Council Fellow at NASA/Ames Research Center. He holds a Ph.D. in Biology/Physiology from SUNY Binghamton.
- Venture capitalist at CincyTech, leading multiple successful life science investments
- Chairman, Invirsa
Dr. Samuel Lee co-founded Eikonoklastes in 2019 and has served as a member of our Board of Directors and Chief Business Officer since 2019. Dr. Lee brings a multidisciplinary convergence of experiences in the life sciences, physical sciences, and computer sciences to successfully develop breakthroughs in healthcare. Prior to Eikonoklastes, Sam was a Director at CincyTech, a venture capital firm, where he led investments and actively supported operations in biotech and medical device portfolio companies such as Myonexus (acquired by Sarepta), Standard Bariatrics (acquired by Teleflex), and Blue Water Vaccines (NASDAQ: BWV).
Dr. Lee completed his medical training at the University of Cincinnati, formal business and public health education at the Stanford Graduate School of Business and Johns Hopkins, and post-graduate research fellowship at Northwestern University and Cincinnati Children’s Hospital Medical Center. Dr. Lee also serves as Chairman of the Board of Directors at Invirsa and is an Executive-in-Residence at CincyTech.
- Extensive experience in early and late phase drug development in multiple therapeutic areas
- 2x founder (LyGenesis and ICaPath) and Director of UPMC’s world renowned Liver Transplant Program, Starzl Transplant Institute
Dr. Paulo Fontes is a transplant surgeon, scientist, and entrepreneur with 30+ years of experience in both cell and organ transplantation and transplant immunology. Dr. Fontes has extensive experience in designing and executing preclinical and early/late-stage clinical trials, including regulatory submissions in both the US and EU. Prior to Eikonoklastes, Paulo was the co-founder and Chief Medical Officer of LyGenesis, a clinical-stage cell therapy company transforming a patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. He was also a co-investigator of the pioneering clinical trials for islet transplantation, bone marrow transplantation, xenografts and LAK cell therapy at the University of Pittsburgh.
Dr. Fontes has also had a decorated career as a faculty member in senior healthcare leadership positions, including serving as Professor of Surgery at the U Pitt, Starzl Transplantation Institute (STI), Department of Surgery, School of Medicine (SOM), University of Pittsburgh Medical Center (UPMC); the Director of the South & America Divisions, UPMC International; Director of UPMC’s Liver Transplant Program, Starzl Transplant Institute, where he led the program to generate >$1B in clinical revenues, while conducting more than 1,500 liver transplants and personally providing for more than 10,000 patients. Paulo was also the co-founder and Medical Director, Organ Referral Center, UPMC which became one of the largest organ referral enterprises in the country and was Deputy Director, McGowan Institute for Regenerative Medicine (MIRM), SOM, U Pitt.
Dr. Fontes was born in Sao Paulo, Brazil, where he graduated from Sao Paulo State University, School of Medicine. He underwent 10 years of post-graduate education, including 3 fellowships after the completion of his residency in general surgery. He is certified by the American Society of Transplant Surgeons and the American College of Surgeons. Dr. Fontes has contributed to over 250 scientific publications (115 peer-review papers, 10 book chapters, and 126 published abstracts) and 7 patents. He was directly involved in the training of more than 90 transplant surgeons and has continued to teach and mentor medical students at the SOM, U Pitt, in addition to bioengineer students at Carnegie Mellon University, Pittsburgh, PA. Dr. Fontes has continuously supported and guided young entrepreneurs through his associations and ongoing interactions with MassBio, MA; NYBio, NY; LifeX, Pittsburgh, PA, XLerateHealth, Louisville, KY; Texas Medical Center Innovation Institute, Houston, TX, University of Colorado Anschutz, Aurora, CO and WVU, Morgantown, WV.
- World leading expert in Caveolin biology
- Inventor of Eikonoklastes gene therapy platform
- Pioneer in Tissue Factor biology
- Inventor of Eikonoklastes immunotherapy platform
- Leading expert in antibody and gene therapy manufacturing for several successful private and publicly traded biotech companies
Dr. Vishal Agrawal joined Eikonoklastes in 2022 as our Vice President of CMC and Process Development. Prior to joining Eikonoklastes, Vishal worked at a number of successful private and publicly-traded biotech companies with increasing responsibility in both antibody and gene therapy manufacturing. Dr. Agrawal completed his Bachelors and Masters in Biochemical Engineering at The Indian Institutes of Technology Delhi and his PhD in Cell Biology at Max-Delbruck Centre.
Professor of Anesthesiology, University of California – San Diego
Director, Gene Therapy Institute, Ohio State University
Professor of Neuroscience, Ohio State University College of Medicine
Former Head of Global Technical Operations, Sarepta
Former Global Head of Biologics and New Modality Development, Takeda
Professor of Neurology, Harvard Medical School
Professor of Neurology, University of Sheffield
Distinguished Professor of Neuroscience, University of California – San Diego
Chief Executive Officer
Chief Business Officer
Elk Capital Markets